Rocket Pharmaceuticals (RCKT) Retained Earnings (2014 - 2026)

Rocket Pharmaceuticals has reported Retained Earnings for 13 years, with the latest figure at -$112000.0 in Q1 2026.

• Quarterly Retained Earnings fell 100.01% year-over-year to -$112000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$112000.0 (down 100.01% YoY) and the FY2025 annual result came in at -$31000.0, down 146.97% from the prior year.
• Retained Earnings eased to -$112000.0 in Q1 2026 per RCKT's latest filing, from -$31000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $1.7 billion in Q1 2025 and troughed at -$1.2 billion in Q3 2024.
• A 5-year average of $210.6 million and a median of -$107000.0 in 2025 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 1624716.67% in 2024, down 180.38% in 2024.
• Over 5 years, Retained Earnings stood at -$713.8 million in 2022, then surged by 303.25% to $1.5 billion in 2023, then tumbled by 100.0% to $66000.0 in 2024, then slumped by 146.97% to -$31000.0 in 2025, then plunged by 261.29% to -$112000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$112000.0, -$31000.0, and -$9000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.